Leeward Investments LLC MA Cuts Stock Position in Cencora, Inc. $COR

Leeward Investments LLC MA lowered its stake in Cencora, Inc. (NYSE:COR) by 5.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 36,091 shares of the company’s stock after selling 2,061 shares during the quarter. Leeward Investments LLC MA’s holdings in Cencora were worth $12,190,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vestcor Inc grew its stake in shares of Cencora by 0.5% in the 3rd quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after buying an additional 28 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in Cencora by 30.2% during the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after purchasing an additional 29 shares during the last quarter. Cornerstone Wealth Group LLC boosted its stake in Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after purchasing an additional 30 shares during the last quarter. Apollon Wealth Management LLC boosted its stake in Cencora by 0.5% during the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after purchasing an additional 30 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 31.4% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $43,000 after purchasing an additional 33 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $261.16 on Friday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market cap of $50.81 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.18 and a beta of 0.64. The stock’s fifty day moving average is $316.88 and its 200 day moving average is $339.79.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the company posted $4.42 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.76 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Ratings Changes

Several analysts have commented on COR shares. Robert W. Baird cut their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Citigroup cut their target price on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. William Blair started coverage on Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.